Kuros Biosciences AG (KURN) - Total Assets
Based on the latest financial reports, Kuros Biosciences AG (KURN) holds total assets worth CHF109.97 Million CHF (≈ $139.03 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See KURN net asset value for net asset value and shareholders' equity analysis.
Kuros Biosciences AG - Total Assets Trend (2004–2024)
This chart illustrates how Kuros Biosciences AG's total assets have evolved over time, based on quarterly financial data.
Kuros Biosciences AG - Asset Composition Analysis
Current Asset Composition (December 2024)
Kuros Biosciences AG's total assets of CHF109.97 Million consist of 52.9% current assets and 47.1% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 20.7% |
| Accounts Receivable | CHF14.93 Million | 17.7% |
| Inventory | CHF9.44 Million | 11.2% |
| Property, Plant & Equipment | CHF3.72 Million | 4.4% |
| Intangible Assets | CHF14.99 Million | 17.7% |
| Goodwill | CHF19.43 Million | 23.0% |
Asset Composition Trend (2004–2024)
This chart illustrates how Kuros Biosciences AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Kuros Biosciences AG.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kuros Biosciences AG's current assets represent 52.9% of total assets in 2024, a decrease from 76.1% in 2004.
- Cash Position: Cash and equivalents constituted 20.7% of total assets in 2024, down from 23.8% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is goodwill at 23.0% of total assets.
Kuros Biosciences AG Competitors by Total Assets
Key competitors of Kuros Biosciences AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Sino Medical Sciences Technology In
SHG:688108
|
China | CN¥1.34 Billion |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$127.41 Million |
|
Beijing Succeeder Technology Inc
SHG:688338
|
China | CN¥1.75 Billion |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.00 Billion |
|
Respiri Ltd
AU:RSH
|
Australia | AU$7.08 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €57.17 Million |
|
Atomo Diagnostics Ltd
AU:AT1
|
Australia | AU$9.48 Million |
Kuros Biosciences AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.25 | 2.73 | 5.73 |
| Quick Ratio | 1.74 | 2.17 | 5.34 |
| Cash Ratio | 0.68 | 0.00 | 4.92 |
| Working Capital | CHF33.76 Million | CHF21.08 Million | CHF14.65 Million |
Kuros Biosciences AG - Advanced Valuation Insights
This section examines the relationship between Kuros Biosciences AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.90 |
| Latest Market Cap to Assets Ratio | 11.70 |
| Asset Growth Rate (YoY) | 18.3% |
| Total Assets | CHF84.54 Million |
| Market Capitalization | $988.78 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Kuros Biosciences AG's assets at a significant premium (11.70x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Kuros Biosciences AG's assets grew by 18.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Kuros Biosciences AG (2004–2024)
The table below shows the annual total assets of Kuros Biosciences AG from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CHF84.54 Million ≈ $106.88 Million |
+18.29% |
| 2023-12-31 | CHF71.46 Million ≈ $90.35 Million |
-13.84% |
| 2022-12-31 | CHF82.95 Million ≈ $104.87 Million |
-9.19% |
| 2021-12-31 | CHF91.34 Million ≈ $115.47 Million |
-3.21% |
| 2020-12-31 | CHF94.36 Million ≈ $119.30 Million |
+7.41% |
| 2019-12-31 | CHF87.85 Million ≈ $111.07 Million |
+2.37% |
| 2018-12-31 | CHF85.82 Million ≈ $108.50 Million |
-0.30% |
| 2017-12-31 | CHF86.08 Million ≈ $108.83 Million |
+96.68% |
| 2016-12-31 | CHF43.77 Million ≈ $55.33 Million |
+1242.99% |
| 2015-12-31 | CHF3.26 Million ≈ $4.12 Million |
-81.52% |
| 2014-12-31 | CHF17.63 Million ≈ $22.29 Million |
-56.47% |
| 2013-12-31 | CHF40.50 Million ≈ $51.21 Million |
+33.27% |
| 2012-12-31 | CHF30.39 Million ≈ $38.42 Million |
-1.37% |
| 2011-12-31 | CHF30.81 Million ≈ $38.96 Million |
-43.01% |
| 2010-12-31 | CHF54.07 Million ≈ $68.36 Million |
-21.30% |
| 2009-12-31 | CHF68.70 Million ≈ $86.86 Million |
-37.97% |
| 2008-12-31 | CHF110.75 Million ≈ $140.02 Million |
-10.36% |
| 2007-12-31 | CHF123.56 Million ≈ $156.21 Million |
+115.21% |
| 2006-12-31 | CHF57.41 Million ≈ $72.58 Million |
-30.32% |
| 2005-12-31 | CHF82.39 Million ≈ $104.17 Million |
-6.76% |
| 2004-12-31 | CHF88.37 Million ≈ $111.72 Million |
-- |
About Kuros Biosciences AG
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technol… Read more